All clinical samples were collected in the Veterinary Hospital of the University of Guadalajara (Guadalajara, Jalisco, Mexico), which offers veterinary services to the city of Guadalajara and its metropolitan areas comprised of Zapopan, Tlaquepaque, Tonala, and Tlajomulco. Samples of all parvovirus suspect cases were collected from October 2013 through April 2014 by rectal swab from vaccinated and unvaccinated diarrheic dogs. In addition, information such as date of sampling, age, sex, breed, housing location, and clinical history were recorded. Samples were collected in duplicate and frozen at −20°C.
DNA preparation was performed with some modifications, as previously described. 18, 22 In brief, samples were thawed at room temperature and homogenized in 1 ml of saline solution and clarified by centrifugation at 10,000 RCF for 5 min. Next, samples were diluted 1:10 in distilled water and heated for 10 min at 98°C followed by 5 min at 4°C in a thermal cycler. a Polymerase chain reaction (PCR) amplification of the vp2 gene was performed with oligonucleotides b forward (5′-GGAAACCAACCATACCAACTCC-3′) and reverse (5′-GGATTCCAAGTATGAGAGGC-3′) as previously described, 17 which generated an amplicon of 1,042 bp from position 3385 to 4426. The PCR reactions were performed with 3 μl of DNA sample, 2.5 μl of 10× PCR buffer, 10 pmol/l of each primer, 0.5 μl of 10 mmol/l deoxyribonucleotide triphosphate mix, and 0.3 μl of Taq DNA polymerase c (5 U/μl) in a final volume of 25 μl. Thermal cycler conditions were initial denaturation at 94°C for 5 min, followed by 30 cycles of denaturation at 94°C for 30 sec, annealing at 50°C for 1 min, and extension at 72°C for 1 min and a final extension at 72°C for 10 min. The PCR products were separated in a 7% polyacrylamide gel electrophoresis and silver-stained. All PCR-positive samples for the 1,042-bp amplicon were frozen for further restriction fragment length polymorphism (RFLP) analysis. Commercial live attenuated vaccine d was used as a positive control, and 5 fecal samples from healthy dogs were used as negative controls.
The RFLP analysis was performed as previously described. 3, 18 In brief, 5 μl of the 1,042-bp amplicon was digested with 2 U of the restriction enzyme MboII e in the presence of 1 μl of 10× CutSmart buffer e and 3 μl of distilled water in a final volume of 10 μl. The reactions were incubated at 37°C for 1 hr. Samples were subjected to 7% polyacrylamide electrophoresis and silver stain. Cleavage pattern of the 1,042-bp amplicon was recorded. The 1,042-bp amplicon was subjected to DNA sequencing in both strands using the oligonucleotides described above. The sequencing process was made in a commercial sequencer. f DNA sequences were analyzed, g and amino acid sequences were deduced h and aligned. i Sequences described in the present study were submitted to GenBank, and accession numbers are described in Table 2 . The CPV-2c reference sequences obtained from GenBank (Ecuador, KF149984.1, KF149971.1; Uruguay, KC196109.1, KC196108.1; Italy, FJ222821.1, FJ005249.1) were used for comparison purposes.
A total of 41 samples were collected from suspected dogs, and after PCR screening, 24 (58%) were positive for the 1,024-bp amplicon. In a similar way, the live attenuated vaccine showed a same sized band. Nonspecific bands were observed in the 5 samples obtained from healthy dogs. All 24 samples showed a RFLP pattern associated with the viral variant CPV-2c, which consisted of 3 bands of 634, 352, and 56 bp. Live attenuated vaccine was used as an internal control and showed a pattern associated with CPV-2a and CPV-2b that comprised 2 bands of 634 and 408 bp. This last result is coherent because the commercial vaccine used in the current study was the Cornell strain-based vaccine. As shown in Table 1 , from the 24 diagnosed dogs with CPV, 16 (67%) were 6 months or younger, 3 (12%) ranged from 7 to 12 months, and 1 (4%) ranged from 13 to 15 months. Fourteen dogs (58%) were referred to as "never vaccinated," and 7 (29%) dogs received an incomplete vaccine regimen against CPV; none of the dogs treated in the hospital showed a complete vaccination schedule.
Five random samples were sequenced, and analysis confirmed the sole presence of CPV-2c viral variant with the characteristic presence of glutamic acid at position 426. DNA BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) comparison analysis showed a 98-99% similarity with most sequences reported in GenBank; however, the sequences showed a 99-100% similarity at the amino acid level with most sequences reported worldwide. At the nucleotide level, CPV-2c sequence comparison against isolates from Ecuador, Uruguay, and Italy showed several single nucleotide polymorphisms (SNPs). First of all, a nonsynonymous mutation was identified at position 3442 of the isolate MX-GDL/6/11/13, which showed a transition (ATA to ATG) in the third position of codon 219. This change replaced the amino acid isoleucine for methionine (Ile to Met), and, to the authors' knowledge, the replacement has not been reported elsewhere. Additionally, 7 synonymous SNPs were identified along the DNA sequence. For instance, in isolates MX-GDL/2/10/13 and MX-GDL/24A/2/14 at position 3583, a transition (TTT to TTC) in the third position of the codon was identified. Full descriptions of the SNPs identified in the present study are described in Table 2 .
Since its description in 1970, CPV-2 has had a worldwide distribution causing high levels of morbidity and mortality in dog populations. Although dogs from all ages are susceptible to acquire the infection, puppies or dogs less than 6 months of age have a higher predisposition for developing the disease. 12 As shown in Table 1 , dogs diagnosed with the virus (67%) were not older than 6 months; this is a relatively low number of infected dogs when compared with reports where an incidence of 95% was determined. 19 However, in the current study, 16% of dogs diagnosed with the virus ranged from 7 to 15 months. This most likely occurred because the majority of dogs tested did not have a vaccination program or were not vaccinated against the virus, therefore increasing the risk of infection.
Canine parvovirus 2c has been distributed worldwide and is cocirculating with the antigenic variants CVP-2a and CPV-2b. In western Europe, for example, samples analyzed from Germany, France, and Bulgaria have shown a cocirculation of CPV-2a and 2c, CPV-2b and 2c, and CPV-2a and 2b, respectively. 7, 9 In contrast, in Hungary and Albania, the main circulating variant is CPV-2a. 4, 5 These findings contrast sharply with reports from South American countries where the main CPV variant type is 2c, as it has been reported in Ecuador 1 (54%), Brazil 19 (78%), and Uruguay 17,18 (96%). In the current study, all samples collected in western Mexico showed a dominant frequency of the CPV-2c variant as shown in Table 1 . This frequency is only comparable with studies reported previously in Uruguay, where 24 of 25 samples analyzed were type 2c. 18 In Mexico, it might be possible that CPV-2c has displaced CPV-2a and CPV-2b in the region and possibly throughout the country. These findings may not be surprising because viral displacement has been reported previously in Italy 13 and Uruguay. 18 However, it is difficult to asseverate this suggestion because there is a lack of previous related studies in Mexico with which to compare the viral dynamics.
Although several nucleotide mutations or SNPs where identified in samples analyzed in the present study, most of them were silent with no impact in the codified amino acid. Interestingly, the isolate MX-GDL/6/11/13 presented a point mutation (ATA to ATG) that replaced the residue isoleucine for methionine (Ile to Met) at codon 219. This mutation has not been reported previously, to the authors' knowledge, and a more in-depth analysis of samples is necessary in order to determine if this replacement might play a key role in viral local adaptation ( Table 2 ). Analysis of changes in critical amino acid positions related with host changes and adaptations, 15 such as 297, 300, 305, 323, and 440 of the VP2 protein, of the virus did not show substitutions in reference to viral variants from Italy, Ecuador, and Uruguay. The presence of alanine (Ala) residue located at position 297 instead of serine (Ser) residue has been proposed as a key player in the process of local adaptation and is possibly related with a viral escape of the immune system in vaccinated animals. 16 All analyzed samples herein showed the alanine (Ala) residue at position 297. A similar finding was found in isolates from South America, and this supports the notion that this amino acid substitution is increasing in frequency around the world. In conclusion, the current study demonstrates a dominant occurrence of CPV-2c in the western Mexico region, and further studies are needed in order to determine if this CPV-2c dominance is present in other regions of Mexico.
